Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced the appointment of Daniel B. Gilmer, Ph.D., to its board of directors, effective April 24, 2026.

Gilmer currently serves as Senior Director, Commercial Quality U.S. Team Lead at Pfizer Inc., a position he has held since February 2025. At Pfizer, he leads an organization responsible for quality and promotional review across more than 50 U.S. brands.

From April 2022 to February 2025, Gilmer led cross-functional teams in Pfizer's Antiviral and Diagnostics Business, where he launched Paxlovid in the United States as it received New Drug Approval from the U.S. Food and Drug Administration. He joined Pfizer in May 2019 in the Research & Development division.

Before joining Pfizer, Gilmer worked at McKinsey & Co. focusing on commercial growth strategies, market access, and lean manufacturing. He also conducted microbiology and infectious disease research at academic institutions and the National Institutes of Health.

Gilmer is a co-inventor on the patent for Exebacase, a Streptococcus bacteriophage lysin that received Fast Track and Breakthrough Therapy designations from the FDA before advancing to Phase 3 clinical trials. He holds a Ph.D. in Microbiology from Rockefeller University and a B.S. from Howard University.

"Daniel has discovered and helped advance first-in-class anti-infective candidates and has played pivotal roles in the launch and commercialization of breakthrough therapies and diagnostics," stated Robin C. Kramer, Chair of Armata's Board of Directors.

Armata is a late clinical-stage biotechnology company focused on developing bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.